Perspective Therapeutics (CATX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CATX Perspective Therapeutics

Watchlist

3.4700
+0.4700+15.67%

Close Nov 22 16:00 ET

3.4500
-0.0200-0.58%

Pre 04:04 ET

234.53MMarket Cap-2328P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Perspective Therapeutics Price Target Cut to $16.00/Share From $22.00 by Oppenheimer
Dow JonesNov 22 09:32 ET · Ratings
Perspective Therapeutics Is Maintained at Outperform by Oppenheimer
Dow JonesNov 22 09:32 ET · Ratings
Perspective Therapeutics Analyst Ratings
BenzingaNov 22 09:20 ET · Ratings
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16
Moomoo NewsNov 22 08:31 ET · Ratings
Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)
TipRanksNov 22 07:15 ET · Ratings
Perspective Therapeutics Selloff a Buying Opportunity, Says JonesResearch
TipRanksNov 22 06:00 ET

Comments

Jaguar8

Nov 22 13:52

Easy 16% 😉

$Perspective Therapeutics (CATX.US)$

Johnny Mnemonic

Nov 22 10:12

I don't trust nobody
I don't even trust my mind
losing everybody
they can never take my grind

Jaguar8

Nov 21 23:09

On watchlist. Reason: Presentation today. Possible PR tomorrow

$Perspective Therapeutics (CATX.US)$

Stock_Drift

Nov 15 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Nov 15 15:13

Watching! Note the dates!

$Perspective Therapeutics (CATX.US)$ Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium t...